ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart, News: TSX:PLI) reported its fourth quarter and fiscal 2012 results yesterday. The company narrowed its losses to just $400,000 on revenue of $23.3-million, up from 2011 $17.6-million topline. ProMetic lost $3.3-million last year.
CEO Pierre Laurin said he believes the year will set up those to come.
“Two thousand twelve was a record year for ProMetic, with the highest annual sales in our corporate history. Two thousand twelve was also a pivotal year in terms of closing new strategic partnerships and alliances in both established and emerging markets. We are proud to have exceeded our corporate objectives set for the year and look forward to a strong 2013 as we continue to position ProMetic’s technologies as new industry standards,” he said. “We believe that the necessary foundation to achieve the next stage of corporate growth has been firmly established for 2013 and the coming years.”
2013 has continued a minor resurgence in shares of ProMetic that began last autumn, when its stock bottomed at a dime. The company’s share price began to stir when China-based Shenzhen Hepalink Pharmaceutical took a 10% stake with a $10-million equity investment in ProMetic last October, and was bolstered in January when it received confirmation from partner Octapharma of the regulatory approval of Octaplas by the FDA for the U.S. market. Octaplas, a treatment for patients with blood clotting disorders, has already treated more than two-million patients outside the United States, and incorporates ProMetic’s PrioClear into its manufacturing process.
Founded in 1992, Laval-based ProMetic Life Sciences designs technology that is used to remove pathogens from blood, and extract and recover proteins from plasma. The company has a number of therapeutics and protein technologies that target everything from Chemotherapy-induced anemia, to Cancer related anemia, to its Prion Capture Technology, which enhances detection of “mad cow disease” in cattle.
At press time, shares of ProMetic were down 2.2% to $.44.
Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]
Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]
The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]
Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]
He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]
Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]